[Federal Register Volume 64, Number 18 (Thursday, January 28, 1999)]
[Notices]
[Pages 4454-4455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-1963]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Oncogene
[[Page 4455]]
Deregulation Tumor Suppressor Gene Loss of Function in CLL.
Date: March 3, 1999.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: 6130 Executive Boulevard, Rockville, MD 20852.
Contact Person: Kevin Ryder, Scientific Review Administrator,
Grants Review Branch, National Cancer Institute, EPN Room 635, 6130
Executive Blvd. MSC 7408, Bethesda, MD 20892-7408, 301-402-2785.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: January 22, 1999.
LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 99-1963 Filed 1-27-99; 8:45 am]
BILLING CODE 4140-01-M
